U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Ovemotide, a melanoma peptide vaccine that was investigated as an antineoplastic agent. Information about the current use of this compound is not available.

Approval Year

Unknown
149124
Name Type Language
OVEMOTIDE
INN   USAN  
INN   USAN  
Official Name English
MPS-21
Preferred Name English
MELAN-A(AA26-35*A27L))
Common Name English
(264-L-VALINE)MELANOCYTE PROTEIN PMEL 17 (HUMAN MELANOMA-ASSOCIATED ME20 ANTIGEN)-(256-264)-PEPTIDE
Common Name English
L-VALINE, L-TYROSYL-L-LEUCYL-L-.ALPHA.-GLUTAMYL-L-PROLYLGLYCYL-L-PROLYL-L-VALYL-L-THREONYL-
Common Name English
MART-1:26-35(27L) PEPTIDE
Common Name English
ovemotide [INN]
Common Name English
(LEU27)-MELAN-A, MART 1 (26-35)
Common Name English
TYR-LEU-GLU-PRO-GLY-PRO-VAL-THR-VAL
Common Name English
Ovemotide [WHO-DD]
Common Name English
ELAGIGILTV
Common Name English
GP100:280-288(288V) PEPTIDE
Common Name English
OVEMOTIDE [USAN]
Common Name English
Code System Code Type Description
CAS
181477-91-8
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
INN
8709
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL263441
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
RXCUI
1427208
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY RxNorm
SMS_ID
100000175345
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
FDA UNII
704120HM0H
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
USAN
RR-79
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
NCI_THESAURUS
C166973
Created by admin on Mon Mar 31 18:23:31 GMT 2025 , Edited by admin on Mon Mar 31 18:23:31 GMT 2025
PRIMARY
ACTIVE MOIETY
OVEMOTIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966